Ardelyx, Inc. ARDX

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

• GlobeNewswire Inc. 2 oct

  ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

  Rosen Law Firm is reminding investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 of an important November 16, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA.

  

• GlobeNewswire Inc. 29 sept

  INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in XTI Aerospace, Inc. of Class Action Lawsuit and Upcoming Deadlines – XTIA

  Pomerantz Law Firm has filed class action lawsuits against XTI Aerospace, Baidu, and Ardelyx for alleged securities fraud and unlawful business practices. XTI Aerospace experienced a significant stock price decline of 15.92% following disclosure of an internal review of its former CEO who resigned on August 17, 2026. Investors have until October 27, 2026, to request Lead Plaintiff status.

  

• GlobeNewswire Inc. 25 sept

  ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX

  Rosen Law Firm has filed a class action lawsuit on behalf of Ardelyx, Inc. (NASDAQ: ARDX) investors who purchased stock between January 13, 2025 and August 6, 2026. The lawsuit alleges that defendants made materially false and misleading statements about the company's commercial performance and growth prospects for drugs XPHOZAH and IBSRELA, while concealing information about payer-related access barriers, prior authorization requirements, and step edit requirements that hindered patient access and new-patient starts. The deadline to serve as lead plaintiff is November 16, 2026.

  

• GlobeNewswire Inc. 25 sept

  ARDX Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ardelyx, Inc. Securities Class Action Lawsuit

  Robbins LLP reminds investors of the November 16, 2026 lead plaintiff deadline in a securities class action against Ardelyx, Inc. (ARDX). The lawsuit alleges the company misled investors about commercial performance and growth prospects for its drugs ISBRELA and XPHOZAH, concealing material adverse facts about payer access barriers and reimbursement challenges. On August 6, 2026, Ardelyx reduced its 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance, causing the stock to drop 18% in one day from $4.87 to $4.00 per share.

  

• GlobeNewswire Inc. 25 sept

  ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law

  Schall, Brown & Schwartz LLP has filed a class action lawsuit against Ardelyx, Inc. for alleged securities violations under the Securities Exchange Act of 1934. The lawsuit claims the company made false and misleading statements regarding reimbursement barriers that impacted patient access to its drugs XPHOZAH and IBSRELA, causing delays in new-patient starts and prescription fulfillment. The class period runs from January 13, 2025 to August 6, 2026, with a deadline of November 16, 2026 for shareholders to participate.